Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway

Pijian Yang1,*, Yuzhen Liang2,*, Yunchen Luo,2 Zhengming Li,2 Yumei Wen,1 Jing Shen,1 Ruwen Li,1 Hua Zheng,3 Harvest F Gu4,*, Ning Xia1,*1Department of Endocrinology and Metabolism, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, People’s Republic of China; 2De...

Full description

Bibliographic Details
Main Authors: Yang P, Liang Y, Luo Y, Li Z, Wen Y, Shen J, Li R, Zheng H, Gu HF, Xia N
Format: Article
Language:English
Published: Dove Medical Press 2019-07-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
Glucagon like peptide 1
Liraglutide
Nonalcoholic fatty liver disease
Insulin resistance
Insulin signaling
Online Access:https://www.dovepress.com/liraglutide-ameliorates-nonalcoholic-fatty-liver-disease-in-diabetic-m-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/liraglutide-ameliorates-nonalcoholic-fatty-liver-disease-in-diabetic-m-peer-reviewed-article-DMSO

Similar Items